Emerging drugs for the treatment of perennial allergic rhinitis

References

• Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update. Allergy. 2008;63(Suppl 86):8–160.
   PubMed Web of Science ®Google Scholar
• Katelaris CH, Lee BW, Potter PC, et al. Prevalence and diversity of allergic rhinitis in regions of the world beyond Europe and North America. Clin Exp Allergy. 2012;42:186–207.
   PubMed Web of Science ®Google Scholar
• Roberts G, Xatzipsalti M, Borrego LM, et al. Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. Allergy. 2013;68:1102–1116.
   PubMed Web of Science ®Google Scholar
• Mallol J, Crane J, Von Mutius E, et al. The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three: a global synthesis. Allergol Immunopathol (Madr). 2013;41:73–85.
   PubMed Web of Science ®Google Scholar
• Wheatley LM, Togias A. Clinical practice. Allergic rhinitis. N Engl J Med. 2015;372:456–463.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Schünemann HJ, Samolinski B, et al. Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol. 2012;130:1049–1062.
   PubMed Web of Science ®Google Scholar
• Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126:466–476.
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Incorvaia C, Scurati S, et al. Patient-related factors in rhinitis and asthma: the satisfaction with allergy treatment survey. Curr Med Res Opin. 2011;27:1005–1011.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Schunemann HJ, Fonseca J, et al. MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. Allergy. 2015;70:1372–1392.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Bachert C, Canonica GW, et al. Unmet needs in severe chronic upper airway disease (SCUAD). J Allergy Clin Immunol. 2009;124:428–433.
   PubMed Web of Science ®Google Scholar
• Hellings PW, Fokkens WJ, Akdis C, et al. Uncontrolled allergic rhinitis and chronic rhinosinusitis: where do we stand today?. Allergy. 2013;68:1–7.
   PubMed Web of Science ®Google Scholar
• Rondón C, Campo P, Togias A, et al. Local allergic rhinitis: concept, pathophysiology, and management. J Allergy Clin Immunol. 2012;129:1460–1467.
   PubMed Web of Science ®Google Scholar
• Papadopoulos NG, Bernstein JA, Demoly P, et al. Phenotypes and endotypes of rhinitis and their impact on management: a PRACTALL report. Allergy. 2015;70:474–494.
   PubMed Web of Science ®Google Scholar
• Bousquet PJ, Combescure C, Neukirch F, et al. Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines. Allergy. 2007;62:367–372.
   PubMed Web of Science ®Google Scholar
• Custovic A, Wijk RG. The effectiveness of measures to change the indoor environment in the treatment of allergic rhinitis and asthma: ARIA update (in collaboration with GA(2)LEN). Allergy. 2005;60:1112–1115.
   PubMed Web of Science ®Google Scholar
• Nurmatov U, Van Schayck CP, Hurwitz B, et al. House dust mite avoidance measures for perennial allergic rhinitis: an updated Cochrane systematic review. Allergy. 2012;67:158–165.
   PubMed Web of Science ®Google Scholar
• Licari A, Ciprandi G, Marseglia A, et al. Current recommendations and emerging options for the treatment of allergic rhinitis. Expert Rev Clin Immunol. 2014;10:1337–1347.
   PubMed Web of Science ®Google Scholar
• Church DS, Church MK. Pharmacology of antihistamines. World Allergy Organ J. 2011;4:S22–7.
   PubMedGoogle Scholar
• Simons FE, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol. 2011;128:1139–1150.e4.
   PubMed Web of Science ®Google Scholar
• Church MK, Maurer M, Simons FER, et al. Risk of first-generation H1-antihistamines: a GA2LEN position paper. Allergy. 2010;65:459–466.
   PubMed Web of Science ®Google Scholar
• Berger WE, Meltzer EO. Intranasal spray medications for maintenance therapy of allergic rhinitis. Am J Rhinol Allergy. 2015;29:273–282.
   PubMed Web of Science ®Google Scholar
• Wolthers OD. Impact of inhaled and intranasal corticosteroids on the growth of children. Bio Drugs. 2000;13:347–357.
   Google Scholar
• Patel P, Philip G, Yang W, et al. Randomized, double-blind, placebo-controlled study of montelukast for treating perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2005;95:551–557.
   PubMed Web of Science ®Google Scholar
• Chen ST, Lu KH, Sun HL, et al. Randomized placebo-controlled trial comparing montelukast and cetirizine for treating perennial allergic rhinitis in children aged 2-6 yr. Pediatr Allergy Immunol. 2006;17:49–54.
   PubMed Web of Science ®Google Scholar
• Yilmaz O, Altintas D, Rondon C, et al. Effectiveness of montelukast in pediatric patients with allergic rhinitis. Int J Pediatr Otorhinolaryngol. 2013;77:1922–1924.
   PubMed Web of Science ®Google Scholar
• Jutel M, Agache I, Bonini S, et al. International consensus on allergy immunotherapy. J Allergy Clin Immunol. 2015;136:556–568.
   PubMed Web of Science ®Google Scholar
• Burks AW, Calderon MA, Casale T, et al. Update on allergy immunotherapy: american Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2013;131:1288–1296.
   PubMed Web of Science ®Google Scholar
• Nelson HS. Subcutaneous immunotherapy versus sublingual immunotherapy: which is more effective? J Allergy Clin Immunol Pract. 2014;2:144–149.
   PubMed Web of Science ®Google Scholar
• Price D, Smith P, Hellings P, et al. Current controversies and challenges in allergic rhinitis management. Expert Rev Clin Immunol. 2015;11:1205–1217.
   PubMed Web of Science ®Google Scholar
• Klemas N, Lieberman P, Dowling R. Clinical economics allergic rhinitis. Med Econ. 2015;92:23–25.
   Google Scholar
• Blaiss MS. Allergic rhinitis: direct and indirect costs. Allergy Asthma Proc. 2010;31:375–380.
   PubMed Web of Science ®Google Scholar
• Crown WH, Olufade A, Smith MW, et al. Seasonal versus perennial allergic rhinitis: drug and medical resource use patterns. Value Health. 2003;6:448–456.
   PubMed Web of Science ®Google Scholar
• Scadding GK, Richards DH, Price MJ. Patient and physician perspectives on the impact and management of perennial and seasonal allergic rhinitis. Clin Otolaryngol Allied Sci. 2000;25:551–557.
   PubMed Web of Science ®Google Scholar
• Fromer LM, Blaiss MS, Jacob-Nara JA, et al. Current Allergic Rhinitis Experiences Survey (CARES): consumers’ awareness, attitudes and practices. Allergy Asthma Proc. 2014;35:307–315.
   PubMed Web of Science ®Google Scholar
• Blaiss MS, Fromer LM, Jacob-Nara JA, et al. Current Allergic Rhinitis Experiences Survey (CARES): health-care practitioners’ awareness, attitudes and practices. Allergy Asthma Proc. 2014;35:316–322.
   PubMed Web of Science ®Google Scholar
• Hankin CS, Cox L. Allergy immunotherapy: what is the evidence for cost saving? Curr Opin Allergy Clin Immunol. 2014;14:363–370.
   PubMed Web of Science ®Google Scholar
• Cox L. Allergy immunotherapy in reducing healthcare cost. Curr Opin Otolaryngol Head Neck Surg. 2015;23:247–254.
   PubMed Web of Science ®Google Scholar
• Durham SR. Effect of intranasal corticosteroid treatment on asthma in children and adults. Allergy. 1999;54(Suppl 57):124–131.
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Bensch GW, Storms WW. New intranasal formulations for the treatment of allergic rhinitis. Allergy Asthma Proc. 2014;35(Suppl 1):S11–9.
   PubMed Web of Science ®Google Scholar
• Ahlström-Emanuelsson C, Andersson M, Persson C, et al. Topical treatment with aqueous solutions of rofleponide palmitate and budesonide in a pollen-season model of allergic rhinitis. Clin Exp Allergy. 2004;34:731–735.
   PubMed Web of Science ®Google Scholar
• Stokes JR, Romero FA, Allan RJ, et al. The effects of an H3 receptor antagonist (PF-03654746) with fexofenadine on reducing allergic rhinitis symptoms. J Allergy Clin Immunol. 2012;129:409–412.
   PubMed Web of Science ®Google Scholar
• Barchuk WT, Salapatek AM, Ge T, et al. A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen-induced nasal congestion. J Allergy Clin Immunol. 2013;132:838-46.e1-6.
   PubMed Web of Science ®Google Scholar
• North ML, Walker TJ, Steacy LM, et al. Add-on histamine receptor-3 antagonist for allergic rhinitis: a double blind randomized crossover trial using the environmental exposure unit. Allergy Asthma Clin Immunol. 2014;10:33.
   PubMed Web of Science ®Google Scholar
• Daley-Yates P, Ambery C, Sweeney L, et al. The efficacy and tolerability of two novel H(1)/H(3) receptor antagonists in seasonal allergic rhinitis. Int Arch Allergy Immunol. 2012;158:84–98.
   PubMed Web of Science ®Google Scholar
• Dymista summary of product characteristics. Available from: http://www.medicines.org.uk/emc/medicine/27574/XPIL/Dymista+Nasal+Spray.
   Google Scholar
• Price D, Shah S, Bhatia S, et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. J Investig Allergol Clin Immunol. 2013;23:495–503.
   PubMed Web of Science ®Google Scholar
• Berger WE, Shah S, Lieberman P, et al. Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis. J Allergy Clin Immunol Pract. 2014;2:179–185.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Bachert C, Bernstein J, et al. Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps. Expert Opin Pharmacother. 2015;16:913–928.
   PubMed Web of Science ®Google Scholar
• Klimek L, Bachert C, Mösges R, et al. Effectiveness of MP29-02 for the treatment of allergic rhinitis in real-life: results from a noninterventional study. Allergy Asthma Proc. 2015;36:40–47.
   PubMed Web of Science ®Google Scholar
• [cited 2015 Nov 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT02498509?term=CKD-342&rank=1.
   Google Scholar
• Ciebiada M, Gorska-Ciebiada M, Barylski M, et al. Use of montelukast alone or in combination with desloratadine or levocetirizine in patients with persistent allergic rhinitis. Am J Rhinol Allergy. 2011;25:e1–6.
   PubMed Web of Science ®Google Scholar
• [cited 2015 Nov 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT02552667.
   Google Scholar
• Akdis M. New treatments for allergen immunotherapy. World Allergy Organ J. 2014;7:23.
   PubMedGoogle Scholar
• Couroux P, Patel D, Armstrong K, et al. Fel d 1-derived synthetic peptide immuno-regulatory epitopes show a long-term treatment effect in cat allergic subjects. Clin Exp Allergy. 2015;45:974–981.
   PubMed Web of Science ®Google Scholar
• [cited 2015 Nov 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT01949441.
   Google Scholar
• Aryan Z, Holgate ST, Radzioch D, et al. A new era of targeting the ancient gatekeepers of the immune system: toll-like agonists in the treatment of allergic rhinitis and asthma. Int Arch Allergy Immunol. 2014;164:46–63.
   PubMed Web of Science ®Google Scholar
• Klimek L, Bachmann MF, Senti G, et al. Immunotherapy of type-1 allergies with virus-like particles and CpG-motifs. Expert Rev Clin Immunol. 2014;10:1059–1067.
   PubMed Web of Science ®Google Scholar
• Kuehr J, Brauburger J, Zielen S, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002;109:274–280.
   PubMed Web of Science ®Google Scholar
• Casale TB, Busse WW, Kline JN, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006;117:134–140.
   PubMed Web of Science ®Google Scholar
• Kopp MV, Hamelmann E, Zielen S, et al. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and comorbid seasonal allergic asthma. Clin Exp Allergy. 2009;39:271–279.
   PubMed Web of Science ®Google Scholar
• Kamin W, Kopp MV, Erdnuess F. Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatr Allergy Immunol. 2010;21:e160–5.
   PubMed Web of Science ®Google Scholar
• Klunker S, Saggar LR, Seyfert-Margolis V, et al. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol. 2007;120:688–695.
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Marseglia GL, Castagnoli R, et al. From IgE to clinical trials of allergic rhinitis. Expert Rev Clin Immunol. 2015;11:1321–1333.
   PubMed Web of Science ®Google Scholar
• Di Bona D, Plaia A, Leto-Barone MS, et al. Efficacy of grass pollen allergen sublingual immunotherapy tablets for seasonal allergic rhinoconjunctivitis: a systematic review and meta-analysis. JAMA Intern Med. 2015;175:1301–1309.
   PubMed Web of Science ®Google Scholar
• Calderón MA, Kleine-Tebbe J, Linneberg A, et al. House dust mite respiratory allergy: an overview of current therapeutic strategies. J Allergy Clin Immunol Pract. 2015;3:843–855.
   PubMed Web of Science ®Google Scholar
• Mosbech H, Canonica GW, Backer V, et al. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms. Ann Allergy Asthma Immunol. 2015;114:134–140.
   PubMed Web of Science ®Google Scholar
• Demoly P, Emminger W, Rehm D, et al. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: results from a randomized double-blind, placebo-controlled phase III trial. J Allergy Clin Immunol 2015
   Google Scholar
• [cited 2015 Nov 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT02443805?term=STG320&rank=1.
   Google Scholar
• Casale TB, Stokes JR. Immunotherapy: what lies beyond. J Allergy Clin Immunol. 2014;133:612–619.
   PubMed Web of Science ®Google Scholar
• Senti G, Kündig TM. Intralymphatic immunotherapy. World Allergy Organ J. 2015;8:9.
   PubMed Web of Science ®Google Scholar
• Senti G, von Moos S, Tay F, et al. Determinants of efficacy and safety in epicutaneous allergen immunotherapy: summary of three clinical trials. Allergy. 2015;70:707–710.
   PubMed Web of Science ®Google Scholar
• Holgate S, Casale T, Wenzel S, et al. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol. 2005;115:459–465.
   PubMed Web of Science ®Google Scholar
• Prussin C, Griffith DT, Boesel KM, et al. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol. 2003;112:1147–1154.
   PubMed Web of Science ®Google Scholar
• Holgate S, Smith N, Massanari M, et al. Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy. 2009;64:1728–1736.
   PubMed Web of Science ®Google Scholar
• Licari A, Marseglia A, Caimmi S, et al. Omalizumab in children. Paediatr Drugs. 2014;16:491–502.
   PubMed Web of Science ®Google Scholar
• Licari A, Marseglia G, Castagnoli R, et al. The discovery and development of omalizumab for the treatment of asthma. Exp Opin Drug Discov. 2015;10(9):1–10.
   Web of Science ®Google Scholar
• Casale TB, Bernstein IL, Busse WW, et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol. 1997;100:110–121.
   PubMed Web of Science ®Google Scholar
• Adelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2000;106:253–259.
   PubMed Web of Science ®Google Scholar
• Casale TB, Condemi J, LaForce C, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. Jama. 2001;286:2956–2957.
   PubMed Web of Science ®Google Scholar
• Chervinsky P, Casale T, Townley R, et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2003;91:160–167.
   PubMed Web of Science ®Google Scholar
• Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004;59:709–717.
   PubMed Web of Science ®Google Scholar
• Okubo K, Ogino S, Nagakura T, et al. Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Allergol Int. 2006;55:379–386.
   PubMedGoogle Scholar
• Nagakura T, Ogino S, Okubo K, et al. Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Clin Exp Allergy. 2008;38:329–337.
   PubMed Web of Science ®Google Scholar
• Tsabouri S, Tseretopoulou X, Priftis K, et al. Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials. J Allergy Clin Immunol Pract. 2014;2:332–40.e1.
   PubMed Web of Science ®Google Scholar
• Boyman O, Kaegi C, Akdis M, et al. EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders. Allergy. 2015;70:727–754.
   PubMed Web of Science ®Google Scholar
• Von Gunten S, Cortinas-Elizondo F, Kollarik M, et al. Mechanisms and potential therapeutic targets in allergic inflammation: recent insights. Allergy. 2013;68:1487–1498.
   PubMed Web of Science ®Google Scholar
• Aryan Z, Rezaei N. Toll-like receptors as targets for allergen immunotherapy. Curr Opin Allergy Clin Immunol. 2015;15:568–574.
   PubMed Web of Science ®Google Scholar
• Furukido K, Takeno S, Ueda T, et al. Suppression of the Th2 pathway by suplatast tosilate in patients with perennial nasal allergies. Am J Rhinol. 2002;16:329–336.
   PubMedGoogle Scholar
• Shiraishi Y, Takeda K, Domenico J, et al. Role of prostaglandin D2 and CRTH2 blockade in early- and late-phase nasal responses. Clin Exp Allergy. 2014;44:1076–1082.
   PubMed Web of Science ®Google Scholar
• Krug N, Gupta A, Badorrek P, et al. Efficacy of the oral chemoattractant receptor homologous molecule on TH2 cells antagonist BI 671800 in patients with seasonal allergic rhinitis. J Allergy Clin Immunol. 2014;133:414–419.
   PubMed Web of Science ®Google Scholar
• Horak F, Zieglmayer P, Zieglmayer R, et al. The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial. Allergy. 2012;67:1572–1579.
   PubMed Web of Science ®Google Scholar
• Takahashi G, Asanuma F, Suzuki N, et al. Effect of the potent and selective DP1 receptor antagonist, asapiprant (S-555739), in animal models of allergic rhinitis and allergic asthma. Eur J Pharmacol. 2015;765:15–23.
   PubMed Web of Science ®Google Scholar
• [cited 2015 Nov 13]. Available from: http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-132222.
   Google Scholar
• Rimmer J, Peake HL, Santos CM, et al. Targeting adenosine receptors in the treatment of allergic rhinitis: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy. 2007;37(1):8–14.
   PubMed Web of Science ®Google Scholar
• Bareille P, Murdoch RD, Denyer J, et al. The effects of a TRPV1 antagonist, SB-705498, in the treatment of seasonal allergic rhinitis. Int J Clin Pharmacol Ther. 2013;51:576–584.
   PubMed Web of Science ®Google Scholar